The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis

Journal of Clinical Gastroenterology

Volumn 46, Issue 8, 2012, Pages 709-715

  Hanouneh, Mohamad A ^a   Hanouneh, Ibrahim A ^a   Hashash, Jana G ^b   Law, Ryan ^a   Esfeh, Jamak Modaresi ^a   Lopez, Rocio ^a   Hazratjee, Nyla ^a   Smith, Thomas ^a   Zein, Nizar N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

liver cirrhosis; rifaximin; spontaneous bacterial peritonitis

Indexed keywords

PROTEIN; RIFAXIMIN; SODIUM;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; ASCITES FLUID LEVEL; BACTERIAL PERITONITIS; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PARACENTESIS; PRIORITY JOURNAL; SCORING SYSTEM; SODIUM BLOOD LEVEL;

ADULT; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; FEMALE; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PERITONITIS; RIFAMYCINS; TREATMENT OUTCOME;

EID: 84865511671     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182506dbb     Document Type: Article

References (41)

1. Toledo C, Salmeron JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology. 1993;17:251-257.
2. Runyon BA, McHutchison JG, Antillon MR, et al. Shortcourse versus long-course antibiotic treatment of spontaneous bacterial peritonitis: A randomized controlled study of 100 patients. Gastroenterology. 1991;100:1737-1742.
3. Rimola A, Salmerön JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology. 1995;21:674-679.
4. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985;5:457-462.
5. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology. 1996; 111:1011-1017.
6. Gines P, Rmola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology. 1990; 12:716-724.
7. García-Tsao G, Albillos A, Barden GE, et al. Bacterial translocation in acute and chronic portal hypertension. Hepatology. 1993;17:1081-1085.
8. Llovet JM, Bartolí R, March F, et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: Molecular epidemiologic evidence. J Hepatol. 1998;28:307-313.
9. Chang CS, Chen GH, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28:1187-1190.
10. Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol. 1997;26:1372-1378.
11. Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology. 1984;4:53-58.
12. Lahnborg G, Friman L, Berghem L. Reticuloendothelial function in patients with alcoholic liver cirrhosis. Scand J Gastroenterol. 1981;16:481-489.
13. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986;91:1343-1346.
14. TitöL, Rimola A, Ginè s P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8:27-31.
15. Weinstein MP, Iannini PB, Stratton CW, et al. Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med. 1978;64:592-598.
16. Soriano G, Teixedo M, Guarner C, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology. 1991;100:477-481.
17. Ferná ndez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818-824.
18. Ortiz J, Vila C, Soriano G, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology. 1999;29:1064-1069.
19. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140-148.
20. Berti T., Benoni G., Miglioli P.A., et al. Intestinal antibacterial activity of a new rifamycin derivative: Compound L-105, Chemioterapia (Florence)., 1982. 1. SUPPL4. 106A-111A.
21. Berti T, Benoni G, Miglioli PA, et al. Intestinal antibacterial activity of a new rifamycin derivative: Compound L-105. Chemioterapia (Florence). 1982;1(suppl 4):106A-111A. 21. Miglioli PA, Allerberger F, Calabrò GB, et al. Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. Pharmacol Res. 2001;44:373-375.
22. Debbia EA, Maioli E, Roveta S, et al. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008;20:186-194.
23. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect. 2004;10:1009-1011.
24. Brigidi P, Swennen E, Rizzello F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002;14:290-295.
25. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
26. Peralta S, Cottone C, Doveri T, et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with rifaximin. World J Gastroenterol. 2009;15: 2628-2631.
27. Gionchetti P, Rizzello F, Morselli C, et al. Management of inflammatory bowel disease: Does rifaximin offer any promise? Chemotherapy. 2005;51(suppl 1):96-102.
28. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
29. Runyon BA. Management of adult patients with ascites due to cirrhosis: An update. AASLD practice guidelines. Hepatology. 2009;49:2087-2107.
30. Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009;29:1273-1281.
31. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246-1256.
32. Cunha BA. Antibiotic side effects. Med Clin North Am. 2001;85:149-185.
33. Guarner C, Runyon BA, Heck M, et al. Effect of longterm trimethoprim-sulfamethoxazole prophylaxis on ascites formation, bacterial translocation, spontaneous bacterial peritonitis, and survival in cirrhotic rats. Dig Dis Sci. 1999; 44:1957-1962.
34. Bellot P, García-Pagán JC, Francé s R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52:2044-2052.
35. Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29:992-999.
36. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14: 551-556.
37. Runyon BA, Borzio M, Young S, et al. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis. Hepatology. 1995;21:1719-1724.
38. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res. 1986;12:979-981.
39. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49:467-484.
40. Palazzini E. Periodic Safety Update Report for Rixamin (January 1987-December 2003). Bologna, Alfa Wassermann, 2004.
41. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104:1130-1134.